| DIRECT COMPETITOR COMPARISON | |
| LLY | GSK | NVO | PFE | Industry | | Market Cap: | 42.40B | 107.13B | 39.62B | 147.27B | 130.09M | | Employees: | 40,500 | 99,003 | 28,497 | 81,800 | 181 | | Qtrly Rev Growth (yoy): | 6.80% | 14.90% | 11.30% | -2.90% | 14.60% | | Revenue (ttm): | 21.11B | 45.44B | 10.29B | 45.82B | 31.21M | | Gross Margin (ttm): | 82.33% | 76.27% | 79.57% | 86.61% | 72.61% | | EBITDA (ttm): | 7.74B | 17.91B | 3.56B | 21.31B | -1.66M | | Oper Margins (ttm): | 30.97% | 34.30% | 29.92% | 37.42% | 2.37% | | Net Income (ttm): | -216.00M | 8.16B | 2.19B | 8.09B | N/A | | EPS (ttm): | -0.197 | 3.20 | 3.60 | 1.204 | N/A | | P/E (ttm): | N/A | 13.21 | 18.46 | 15.16 | 13.82 | | PEG (5 yr expected): | 4.05 | 3.06 | 1.19 | 5.99 | 2.20 | | P/S (ttm): | 2.04 | 2.39 | 3.84 | 3.27 | 3.30 |
|
| GSK = GlaxoSmithKline plc | | NVO = Novo Nordisk A/S | | PFE = Pfizer Inc. | | Industry = Drug Manufacturers - Major | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PFE | | The fall of the world's best-selling drug
Fri 7:30pm -
at FT.com | | • | PFE | | This Week's 5 Dumbest Stock Moves
Fri 1:01pm -
at Motley Fool | | • | GSK | | Biotech Bargains for Your Portfolio
Fri 10:58am -
at Motley Fool | | • | GSK | | 7 of the Most Efficient Companies on the Planet
Fri 10:57am -
at Motley Fool | | • | PFE | | Discover This Secret Weapon for Your Portfolio
Fri 10:12am -
at Motley Fool | | • | NVO | | Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
Fri 9:30am -
PR Newswire | | • | GSK | | 3 China Profit Plays
Fri 9:29am -
at Motley Fool | | • | PFE | | Bayer not ruling out large acquisitions - CEO
Fri 6:03am -
at Reuters | | • | GSK | | Theravance, Inc.: Wait to Buy on Dip
Thu 6:19am -
at Seeking Alpha | | • | GSK | | A Schizophrenic Move by Merck?
Wed, Nov 25 -
at Motley Fool | | • | GSK | | Human Genome Begins Trial
Wed, Nov 25 -
Zacks.com | | • | GSK | | [video] Topping the Tape
Tue, Nov 24 -
at CNBC | | • | NVO | | The Complete List of Danish ADR Stocks
Fri, Nov 20 -
at Seeking Alpha | | • | NVO | | Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show
Thu, Nov 19 -
PR Newswire | | • | NVO | | Can This Stock Go Higher?
Wed, Nov 18 -
at Motley Fool | | • | NVO | | Secure Your Future Forever With These Stocks
Tue, Nov 17 -
at Motley Fool | | • | NVO | | Music to Health-Care Investors' Ears
Mon, Nov 16 -
at Motley Fool | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
